Apollo - GLP-1 Treatment Expectations

APOLLO is an integrated health software (not SaMD) designed as an educational tool for GLP-1 patients that feel the lack of clear treatment expectations, one of the primary reasons for early drop-offs.

APOLLO combines proprietary NN clinical trial data with individual user/patient data to provide predictions for weight, HbA1c, and cardiovascular risk reduction, creating a range of benefits for the patients such as realistic patient expectations, increased understanding of the benefits of staying on treatment and improved GLP-1 experience, helping address factors associated with early drop-offs.

The Application Programming Interface (API) nature of APOLLO allows for a modular and agile integration across digital platforms and care journeys for external and internal platforms that support patients beyond the molecule.

APOLLO helps set clearer treatment expectations for GLP-1 patients to address one of the primary reasons for early drop-off.

With its holistic predictions presented in a simple visual format and housed in user-friendly health platforms APOLLO can enhance patient engagement and support a better understanding of the treatment journey.  This can lead to a more informed and engaging treatment experience. By housing APOLLO in their platforms, partners can increase user engagement through simple and data-based predictions built on Novo Nordisk’s proprietary clinical trial data.